Entero Therapeutics, Inc. Cash Flow Conversion Efficiency
Entero Therapeutics, Inc. cash flow conversion efficiency. Based on the latest financial reports, Entero Therapeutics, Inc. (ENTO) has a cash flow conversion efficiency ratio of -0.010x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-855.69K) by net assets ($89.56 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Entero Therapeutics, Inc. (2013–2024)
Cash flow conversion efficiency of Entero Therapeutics, Inc. from 2013 to 2024. This chart illustrates how Entero Therapeutics, Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. View latest Entero Therapeutics, Inc. stock price today for real-time trading data and today's change.
Entero Therapeutics, Inc. Cash Flow Conversion Ratio Explained
Entero Therapeutics, Inc. cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Entero Therapeutics, Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Entero Therapeutics, Inc. ranked by their cash flow conversion efficiency. Also see ENTO market cap overview for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
CytoMed Therapeutics Limited Ordinary Shares
NASDAQ:GDTC
|
-0.299x |
|
CoinSmart Financial Inc
NEO:SMRT
|
-0.279x |
|
ERG S.A.
WAR:ERG
|
0.048x |
|
Titan Logix Corp.
V:TLA
|
-0.028x |
|
T.M.C. Industrial Public Company Limited
BK:TMC
|
-0.065x |
|
Emerge Commerce Ltd
V:ECOM
|
-0.121x |
|
Guardian Exploration Inc
V:GX
|
0.634x |
|
Gullewa Ltd
AU:GUL
|
0.040x |
Annual Cash Flow Conversion Efficiency for Entero Therapeutics, Inc. (2013–2024)
The table below shows the annual cash flow conversion efficiency of Entero Therapeutics, Inc. from 2013 to 2024. Review how much free cash does Entero Therapeutics, Inc. generate to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $57.80 Million | $-9.22 Million | -0.159x | +95.36% |
| 2023-12-31 | $3.60 Million | $-12.38 Million | -3.435x | +57.84% |
| 2022-12-31 | $2.74 Million | $-22.34 Million | -8.148x | -297.39% |
| 2021-12-31 | $-7.82 Million | $-32.29 Million | 4.128x | -2.86% |
| 2020-12-31 | $-2.64 Million | $-11.22 Million | 4.249x | +139914.20% |
| 2019-12-31 | $4.62 Million | $-14.03K | -0.003x | +99.87% |
| 2018-12-31 | $4.47 Million | $-10.87 Million | -2.430x | +7.63% |
| 2017-12-31 | $2.73 Million | $-7.18 Million | -2.630x | -86.35% |
| 2016-12-31 | $3.21 Million | $-4.53 Million | -1.411x | -122950.52% |
| 2015-12-31 | $-3.63 Million | $-4.17K | 0.001x | +400.15% |
| 2014-12-31 | $2.64 Million | $-1.01K | 0.000x | -100.04% |
| 2013-12-31 | $54.60 | $56.55 | 1.036x | -- |
About Entero Therapeutics, Inc.
Entero Therapeutics, Inc. designs and develops an artificial intelligence (AI)-driven software and device platform that enables utilities, retailers, and large power users to manage load and distributed energy resources. The company's Aggregation Management Platform leverages IoT, AI/ML, and edge analytics to forecast, optimize, and dispatch flexible demand. The company also engages in the resear… Read more